S43 The Changing Incidence of Thyroid Cancer

Program: Symposia
Clinical/Translational Session
Friday, March 6, 2015: 4:30 PM-6:00 PM
Room 20A (San Diego Convention Center)
**This session is eligible for CME credit**

Supported by Astra Zeneca LP

Chair:
Julie Ann Sosa, MD, FACS, Duke University, Durham, NC

Nothing to Disclose: JAS

Thyroid cancer incidence is increasing in the United States, as well as other countries around the world. There is signficant controversy if this increased incidence represents an actual increase or is due to the changing approaches to diagnosis. A number of studies have suggested that obesity is associated with an increased risk of thyroid cancer and may be playing a role in the increased incidence of thyroid cancer.

4:30 PM
Steven I Sherman, MD, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Disclosure: SIS: Consultant, Amgen, Member of advisory committees or review panels, Bayer, Inc., Member of advisory committees or review panels, Eisai, Consultant, Eli Lilly & Company, Consultant, Exelixis, Inc., Clinical Researcher, Genzyme Corporation, Member of advisory committees or review panels, Novo Nordisk, Scientific Board Member, Veracyte, Inc..
5:00 PM
Louise Davies, MD, MS, VA Outcomes Group, Hite River Junction, VT
Nothing to Disclose: LD
5:30 PM
Cari Meinhold Kitahara, Ph.D., Radiation Epidemiology Branch, National Institutes of Health, National Cancer Institute, Rockville, MD
Nothing to Disclose: CMK
See more of: Symposia